Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 8/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979358 | 0.88 | LDLR (0.71) | LDLRKMT2AMAPK11KITMAPK14 | |
| SCHEMBL7855514 | 0.88 | LDLR (0.60) | LDLRROCK2PKN2MEN1KMT2A | |
| SCHEMBL2966826 | 0.85 | LDLR (1.00) | LDLRMAPK11KITMAPK14LCK | |
| SCHEMBL2969095 | 0.84 | LDLR (0.52) | LDLRROCK2MAPK14PDE4DPKM | |
| SCHEMBL6782262 | 0.83 | LDLR (0.74) | LDLRROCK2MEN1KMT2AMAPK14 | |
| SCHEMBL241870 | 0.82 | MAPK14 (0.58) | MEN1KMT2AMAPK11MAPK14PDE4D | |
| SCHEMBL27563701 | 0.81 | PDE5A (0.48) | LDLRPDE4DPKMPDE4APDE4B | |
| SCHEMBL4248774 | 0.78 | MEN1 (0.53) | LDLRROCK2PKN2MEN1KMT2A | |
| SCHEMBL3132900 | 0.78 | TDP1 (0.74) | MEN1KMT2AMAPK14PDE4DPDE4A | |
| SCHEMBL13234997 | 0.77 | LDLR (0.67) | LDLRKMT2AKITMAPK14LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1243724-C | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2006-03-01 | — | — | CN | claimed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | claimed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| CN-1330631-A | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2002-01-09 | — | — | CN | claimed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| CN-1243724-C | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2006-03-01 | — | — | CN | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| CN-1330631-A | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2002-01-09 | — | — | CN | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | LDLR 3410/4885ROCK2 2895/4885PKN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.